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PHA406 – Therapeutics B 
DURATION 
 
Reading Time: 10 minutes 
Writing Time: 180 minutes 
 
INSTRUCTIONS TO CANDIDATES 
This examination has 3 (A, B and C) Sections: 
Section A contains Forty (40) Multiple Choice Questions.  Answer ALL questions on the Faculty/School 
supplied Multiple Choice Answer Sheet.  Total marks allocated: Twenty (20). 
Suggested time allocation: Sixty (60) minutes. 
Section B contains Four (4) Extended-Answer Questions.  Answer ALL questions in one of the 16-page 
Booklets provided.  Total marks allocated: Forty (40). 
Suggested time allocation: Sixty (60) minutes. 
Section C contains Two (2) Case Studies.  Answer ALL questions in one of the 16-page Booklets 
provided.  Use a new booklet.  Total marks allocated: Forty (40). 
Suggested time allocation: Sixty (60) minutes. 
 
EXAM CONDITIONS 
You may begin writing from the commencement of the examination session.  The reading time indicated above is 
provided as a guide only. 
This is a CLOSED BOOK examination 
No calculators are permitted 
No handwritten notes are permitted 
No dictionaries are permitted 
ADDITIONAL AUTHORISED MATERIALS EXAMINATION MATERIALS TO BE SUPPLIED 
 




2 x 16 Page Book 
1 x Scrap Paper 
College Multiple Choice Answer Sheet 
 
Family Name  
Given Name/s  
Student Number       
Teaching Period Semester 2, 2018 
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Total No of Marks for this section: 40 
Answer ALL Questions 
 
Answer this section in one of the 16-page Answer Booklets provided. 
Marks for each section are indicated.  Suggested time allocation for Section B: 60 mins 
 
Question 1 (multiple topics) 
Discuss and compare the following aspects of Parkinson’s disease and Alzheimer’s disease: 
 Pathophysiology 
 Clinical presentation 
 Prognosis and aim of therapy 




Question 2 (multiple topics) 
a. Describe and differentiate the pathophysiology of central and nephrogenic diabetes insipidus 
and discuss the therapeutic agents available for the treatment of central diabetes insipidus.  
Include in your answer the mechanism(s) of action of these agents and any adverse effects, 
contraindications and precautions when using these agents. 
 (5 marks) 
b. Discuss how migraine headache can be managed with currently available therapeutic agents.  
Identify those agents which are used for resolving acute migraine and those for prophylaxis.  
Include in your answer a brief description of how they produce their beneficial effects. 
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Question 3 (multiple topics) 
Describe the aetiology, pathophysiology, clinical presentations and management/treatment plan(s) 
for the following disorders/syndromes: 
i. Hyperparathyroidism 
ii. Hepatic encephalopathy 





Question 4 (multiple topics) 
a. A 60-year-old woman with schizophrenia has been taking haloperidol for many years and her 
condition has been well controlled.  However, she has recently started to develop movement 
disorder.  Explain what has probably happened to her (include some possible mechanisms) and 
suggest ONE (1) agent which may be useful to resolve her movement disorder. 
 (5 marks) 
b. Discuss current available pharmacological (include mechanisms of action) and non-
pharmacological therapies for the management of unipolar depression. 





E n d  o f  S e c t i o n  B  
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Total No of Marks for this section: 40 
Answer ALL Questions 
 
Answer this section in one of the 16-page Answer Booklets provided.  Use a new booklet. 
Marks for each section are indicated.  Suggested time allocation for Section C: 60 mins 
 
Case Study 1 (25 marks) 
LH, a 68-year-old female from the remote town of Tennant Creek, is brought to the rural medical 
centre by her family because she has been developing some challenging behaviours since her 
husband passed away a few months ago. 
LH was socially active and able to conduct her routine daily activities with minimal assistance, but 
now she is uncharacteristically moody, with increasing irritability and frustration which has resulted 
in frequent confrontations with her family.  She lacks the desire to do anything she previously 
enjoyed, such as playing bridge (a card game) at the local RSL club and does not want to leave her 
house.  She is also spending less time with her friends and family and regularly locks herself in her 
room. 
LH is an ex-smoker and likes to have a few glasses of her favourite red wine with her dinner.  She also 
consumes a few shots of whisky before going to bed.  Her son reveals that lately, he has noticed she 
has not been eating properly but her alcohol consumption has increased.  She has been rather 
forgetful as well and is not compliant with her medications.  She has not been sleeping well and was 
found pacing around the house during the night on several occasions, sometimes complaining of a 
burning feeling in her stomach and oesophagus. 
On examination, LH appears agitated, disorientated and can only provide ambiguous answer to 
simple questions regarding the current time and her current location.  LH’s other clinical parameters 
include: BP=155/93, heart rate=95 bpm, respiratory rate=27 breaths per minute, 
temperature=38.6C, and SaO2 (blood oxygen saturation) =95%.  Her MMSE (Mini Mental State 
Examination) score is 19/30. 
LH’s medical history includes: 
Hypertension Hypothyroidism 
Type II diabetes mellitus Hepatitis B 
Hyperlipidaemia Total left hip replacement 2 years ago 
Osteoporosis Nocturnal enuresis 
GORD  
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Her current medications include: 
Amlodipine  5mg daily Thyroxine 100g daily before 
breakfast 
Atorvastatin 40mg daily Metformin XR 1.5g daily  
Aspirin 150mg daily MS Contin 20mg bd PRN 
Amitriptyline 75mg at night Pantoprazole 20mg daily PRN 




1 daily Temazepam 10mg at night PRN 
Lantus insulin 16 units at night   
 
Her laboratory test results are: 
Electrolyte  Reference Range Liver Function Test Reference Range 
Na+ 133 135-145mmol/L Albumin  16 32-45g/L 
K+ (serum) 3.9 3.8-4.9mmol/L ALT 46 <35U/L 
Cl- 96 95-110mmol/L ALP 105 25-100U/L 
Urea 6.9 3-8mmol/L GGT 68 <30U/L 
Cr 108 50-110mol/L    
Full blood Examination  Thyroid Function Test  
Hb 154 115-165g/L Free T4 16 10-25pmol/L 
RCC 5.0 3.8-5.8×1012/L TSH 6.6 0.4-5mIU/L 
Hct 0.43 0.37-0.47    
Platelet 350 150-400×109/L Others   
MCV 85 80-100fL CRP 3 <10mg/L 
WCC 9.2 4.0-11.0×109/L BSL (random) 9.2 3-7.7mmol/L 




Please see next page for questions 
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a. Name Five (5) most likely causes of LH’s current clinical presentations.  Explain your 
answers.  
 (10 marks) 
b. Discuss the significance of LH’s liver function tests (LFT) and thyroid function tests 
(TFT) results and identify the potential causes of several abnormal findings.  Suggest 
treatment option(s) you would employ to correct these abnormalities.   
 (5 marks) 
c. Outline the immediate and long-term management plans you would recommend for 
treating LH’s conditions.  Justify your recommendations. 
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Case Study 2 (15 marks) 
SF, a 19-year-old woman is referred to a neurologist for evaluation after experiencing a convulsion 
while jogging.  She is otherwise healthy and takes no medications besides combined oral 
contraceptive pills (COCP).  SF’s boyfriend, who was jogging with her mentions that he did not notice 
any unusual behaviour or symptoms before the onset of her convulsion.  All SF’s medical tests, 
including electrolytes, renal function, complete blood count and head CT scan were normal. 
SF also reveals that for as long as she can remember, flashing lights have caused her to “lose short 
periods of time”.  She also notes that in the morning, her hands occasionally jerk and she may drop 
what she is holding.  SF’s father has had 2 unprovoked convulsions during adulthood and is currently 
taking phenytoin.  SF has no other known risk factors for epilepsy. 
The neurologist makes a presumptive diagnosis of Juvenile Myoclonic Epilepsy (JME) after taking into 
consideration SF’s history of absence seizures, morning myoclonic seizures and one convulsive 
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a. List FIVE (5) risk factors/causes (other than genetic) of seizures. 
 (5 marks) 
b. Discuss the use of sodium valproate rather than carbamazepine in the treatment of SF’s 
JME.  Include in your answer the mechanisms of action and adverse effects associated 
with the use of each agent. 
 (4 marks) 
c. SF is also taking COCP.  Would you suggest any changes to her COCP dosage?  Explain 
your answer. 
 (3 marks) 
d. After a few months, SF marries her boyfriend and decides to become pregnant.  What 
advice or precautionary measures would you provide SF with regarding epilepsy and 
pregnancy, and the use of sodium valproate during pregnancy? 








E nd  o f  S e ct i on  C  
End of  Exam Paper  
 
